Leerink Swann reissued their outperform rating on shares of Illumina, Inc. (NASDAQ:ILMN) in a report released on Tuesday morning. The brokerage currently has a $225.00 price target on the life sciences company’s stock, up from their prior price target of $207.00. Leerink Swann also issued estimates for Illumina’s Q3 2017 earnings at $1.01 EPS, Q4 2017 earnings at $1.19 EPS, Q1 2018 earnings at $1.02 EPS, Q2 2018 earnings at $1.14 EPS, Q3 2018 earnings at $1.18 EPS and FY2018 earnings at $4.60 EPS.
Other equities analysts have also issued reports about the company. Vetr lowered Illumina from a strong-buy rating to a buy rating and set a $197.84 target price for the company. in a research report on Wednesday, May 31st. Zacks Investment Research upgraded Illumina from a hold rating to a buy rating and set a $195.00 target price for the company in a research report on Thursday, July 27th. Canaccord Genuity upgraded Illumina from a hold rating to a buy rating and boosted their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. First Analysis upgraded Illumina from an underweight rating to an equal weight rating and set a $176.00 target price for the company in a research report on Wednesday, August 2nd. Finally, Barclays PLC restated an equal weight rating and set a $150.00 target price on shares of Illumina in a research report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $181.76.
Shares of Illumina (NASDAQ:ILMN) opened at 210.72 on Tuesday. Illumina has a 1-year low of $119.37 and a 1-year high of $214.04. The stock has a market capitalization of $30.77 billion, a price-to-earnings ratio of 42.28 and a beta of 0.81. The firm’s 50-day moving average is $197.88 and its 200-day moving average is $180.42.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.86 earnings per share. On average, analysts predict that Illumina will post $3.65 earnings per share for the current fiscal year.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.11, for a total value of $4,222,200.00. Following the sale, the director now owns 539,176 shares in the company, valued at approximately $113,825,445.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the completion of the sale, the director now owns 534,176 shares in the company, valued at approximately $91,221,235.52. The disclosure for this sale can be found here. Insiders sold a total of 195,434 shares of company stock worth $37,480,647 in the last 90 days. Company insiders own 1.60% of the company’s stock.
Several large investors have recently bought and sold shares of ILMN. Winslow Capital Management LLC acquired a new position in shares of Illumina during the 2nd quarter worth approximately $211,584,000. HPM Partners LLC increased its position in shares of Illumina by 29,103.8% during the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after purchasing an additional 749,424 shares during the last quarter. Fred Alger Management Inc. increased its position in shares of Illumina by 611.9% during the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after purchasing an additional 548,030 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the last quarter. Finally, Capital World Investors increased its position in shares of Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares during the last quarter. 93.34% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.